Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2013 - 2014)
Vertex Pharmaceuticals' (VRTX) quarterly Long-Term Debt Repayments came in at -$140000.0 in Q4 2014, up 11.39% year-on-year from -$125681.8 in Q4 2013, and down 100.05% quarter-over-quarter from $294.4 million in Q3 2014.
Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2013 - 2014) Analysis & Trends
Vertex Pharmaceuticals' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at -$140000.0 for Q4 2014.
- On a quarterly basis, Long-Term Debt Repayments rose 11.39% year-over-year to -$140000.0 in Q4 2014; TTM through Dec 2015 was $294.1 million, a 0.0% change from a year earlier, with the FY2014 full-year figure at $294.2 million, changed N/A from the prior year.
- Long-Term Debt Repayments declined to -$140000.0 in Q4 2014 per VRTX's latest filing, from $294.4 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $294.4 million in Q3 2014 and bottomed at -$158000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -140,000.00 |
| Dec 31, 2014 | -140,000.00 |
| Sep 30, 2014 | 294.38 Mn |
| Sep 30, 2014 | 294.38 Mn |
| Dec 31, 2013 | -158,000.00 |
| Dec 31, 2013 | -158,000.00 |